IntelliHep is exploiting a technology platform to generate novel heparin-based chemical entities, and also pursuing in-house pre-clinical development of lead candidates.
Our team have over 70 years of complementary expertise between them in heparin glycobiology, heparin chemistry, sugar analysis and purification, protein/carbohydrate interactions and screening.
Our R&D portfolio spans generation of novel heparin-based compounds for both in-house and collaborative studies, and developing lead candidates for Alzheimers disease and cancer.